Payment overview · 2025
General Payments
$206.57
12 reported records · 8 companies
Healthcare provider profile · identity verified
Mark C. Dickmeyer, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT WAYNE, IN · NPI 1457349201
Verified facts
What the public records show
CMS Open Payments records show Mark C. Dickmeyer, MD received $206.57 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.06 | 26.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.94 | 21.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.84 | 12.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.07 | 9.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.70 | 9.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.32 | 7.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.09 | 7.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.55 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.57 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $40.93 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 840 | 222 |
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 137 |
| Omeprazole | Omeprazole | 386 | 88 |
| Lisinopril | Lisinopril | 363 | 102 |
| Metformin Hcl | Metformin Hcl | 358 | 101 |
| Losartan Potassium | Losartan Potassium | 356 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 239 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 73 |
| Trazodone Hcl | Trazodone Hcl | 197 | 58 |
| Gabapentin | Gabapentin | 180 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 46 |
| Jardiance | Empagliflozin | 138 | 31 |
| Ozempic | Semaglutide | 137 | 30 |
| Metformin Hcl Er | Metformin Hcl | 133 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 36 |
| Famotidine | Famotidine | 123 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 123 | 34 |
| Allopurinol | Allopurinol | 122 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 34 |
| Simvastatin | Simvastatin | 119 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 37 |
| Furosemide | Furosemide | 113 | 44 |
| Potassium Chloride | Potassium Chloride | 107 | 31 |
| Carvedilol | Carvedilol | 103 | 36 |
| Sertraline Hcl | Sertraline Hcl | 98 | 29 |
| Spironolactone | Spironolactone | 97 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 27 |
| Ondansetron Odt | Ondansetron | 84 | 17 |
| Meloxicam | Meloxicam | 82 | 25 |
| Trulicity | Dulaglutide | 79 | 13 |
| Alendronate Sodium | Alendronate Sodium | 76 | 23 |
| Atenolol | Atenolol | 72 | 21 |
| Montelukast Sodium | Montelukast Sodium | 70 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 15 |
| Finasteride | Finasteride | 66 | 14 |
| Donepezil Hcl | Donepezil Hcl | 64 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 20 |
| Glipizide Er | Glipizide | 59 | 19 |
| Synthroid | Levothyroxine Sodium | 57 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 30 |
| Ezetimibe | Ezetimibe | 53 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 14 |
| Januvia | Sitagliptin Phosphate | 48 | 12 |
| Ibuprofen | Ibuprofen | 46 | 16 |
| Amoxicillin | Amoxicillin | 44 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | 14 |
| Eliquis | Apixaban | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 12 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.57 · 12 records | Novo Nordisk Inc | AUSTEDO XR, Cologuard Collection Kit, EVENITY, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error